Jonathan Dean, Head of Impact Investing at AXA IM Alts adds, “We are excited to support ENOUGH in its mission to provide a scalable alternative to animal protein, which in turn contributes to the transition towards a more sustainable, climate-aligned food system. Our partnership with ENOUGH demonstrates our continued support for innovative investment solutions that are aligned with our overarching aim to invest in solutions that combat climate change and preserve biodiversity.”
CPT Capital says, “ENOUGH excites because of their B2B focus and their ability to create impact and scale within a short timescale. ENOUGH will provide a sustainable alternative to the problem of factory farming / intensive animal agriculture.”
Producing vast quantities of healthy and sustainable protein is one of the most urgent global priorities. ENOUGH addresses this by growing ABUNDA mycoprotein, an existing advantaged ingredient with an established market role, more sustainably and at a lower cost than other protein options.
ENOUGH is building a first of its kind protein factory which will initially produce 10,000 tonnes per annum and which targets producing over a million tonnes by 2032. The plans are supported and have received funding from the Bio-Based Industries Joint Undertaking within the European Union’s Horizon 2020 research and innovation programme under grant agreement No 838104-Plenitude.
As a sustainable food ingredient company who are founded in Glasgow, ENOUGH looks forward to the participating at COP26 in November of this year, where it will highlight the merits of a high scale impactful solution as part of the accepted need for sustainable food.
